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Background: Patients with malignant melanoma may develop brain metastases during the course of the disease,
requiring radiotherapeutic treatment. In patients with 1–3 brain metastases, radiosurgery has been established as a
treatment option besides surgery. For patients with 4 or more brain metastases, whole brain radiotherapy is
considered the standard treatment. In certain patients with brain metastases, radiation treatment using whole brain
helical Tomotherapy with integrated boost and hippocampal-sparing may improve prognosis of these patients.
Methods/Design: The present prospective, randomized two-armed trial aims to exploratory investigate the
treatment response to conventional whole brain radiotherapy applying 30 Gy in 10 fractions versus whole brain
helical Tomotherapy applying 30 Gy in 10 fractions with an integrated boost of 50 Gy to the brain metastases as
well as hippocampal-sparing in patients with brain metastases from malignant melanoma. The main inclusion
criteria include magnetic resonance imaging confirmed brain metastases from a histopathologically confirmed
malignant melanoma in patients with a minimum age of 18 years. The main exclusion criteria include a previous
radiotherapy of the brain and not having recovered from acute high-grade toxicities of prior therapies. The primary
endpoint is treatment-related toxicity. Secondary endpoints include imaging response, local and loco-regional
progression-free survival, overall survival and quality of life.
Trial registration: www.drks.de Trial ID: DRKS00005127
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Malignant melanomas (MM) account for 4.3% of all can-
cers in Germany in females and 3.2% in males, respect-
ively [1]. In the last 3 decades, the age standardized
incidence rates in Germany tripled [1]. In general, sur-
vival in these patients is limited, and reported to be
around 4 to 5 months while MM cause 1% of all cancer
deaths [1-3]. With respect to tumor stage, about 10–13%
of patients initially presenting with AJCC Stage III dis-
ease are at risk for brain metastases (BM) [4-7], and 18–
46% of stage IV patients will develop CNS involvement
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reproduction in any medium, provided the orgender, mucosal or head and neck primaries, as well as
deep or ulcerated lesions [9].
Diagnosis of BM from MM is commonly associated
with a poor prognosis. Surgery is evaluated, however le-
sions can be too small for safe neurosurgical resection,
or multiple lesions are diagnosed arguing against a
neurosurgical intervention; this situation holds true for
the majority of MM patients with BM [10].
For multiple metastases standard of care is whole brain
radiotherapy (WBRT) delivered as 40 Gy in 2 Gy fractions,
or 30 Gy in 3 Gy fractions, leading to modest palliation
with median survival times of 3–5 months, and 1-year sur-
vival rates of about 13% [11-18]. Our own data showed me-
dian overall survival of 3.5 months and a 12-months overall
survival rate of 16.5% [19]. Prognostic factors influencing
survival are predominantly the radiation therapy oncologyral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Flow chart of the study.
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and Karnofsky performance score (KPS) [12,20,21]. In pa-
tients with local treatment, such as neurosurgical resection
or stereotactic radiosurgery (SRS) which is commonly
followed by WBRT, progression-free survival, and in some
cases, overall survival can be improved [22,23].
Due to the limited efficacy of WBRT and the advent of
high precision radiosurgery techniques, local radiothera-
peutic treatment with SRS has been established for sub-
groups of patients with BM, especially with 1–3 lesions.
It has been shown that in these patients WBRT plus sur-
gery or SRS leads to an increase of loco-regional control
compared to local treatments alone, but overall survival
is unaltered [23]. However, in this analysis, several tumor
types with high numbers of breast or lung tumors were
included. For MM patients, the clinical efficacy or
WBRT is known to be limited, and therefore, these pa-
tients are even often excluded from trials evaluating effi-
cacy of treatment for BM. Therefore, in patients with
limited intracranial disease (1–3 metastases), SRS can be
chosen as an effective regimen. Several groups have
reported high efficacy of SRS for patients with BM from
MM: Seung and colleagues treated 140 lesions in 46 pa-
tients, with progression-free rates of 86% and 76% at 6
and 12 months, respectively [24,25]; in this group about
50% of the patients had been treated with SRS alone. Pa-
tients with multiple lesions showed a reduced outcome
compared to patients with solitary metastases. Grob and
co-workers published local control rates of 98% at
3 months for 56 metastases in 35 patients treated with
SRS only and without additional WBRT. Median survival
was longer in patients with single lesions, for example
7.5 months versus 4 months [26]. Our own data pub-
lished previously were based on 64 patients treated for
122 lesions: in this group, the local control was 81% at
12 months, and the median survival after treatment
10.6 months [27].
Sterzing et al. could show the possibilities of helical
Tomotherapy in the setting of a re-irradiation for mul-
tiple metastases with a whole brain radiation including a
multifocal simultaneous integrated boost [28]. Neverthe-
less it emphasizes the possibilities of Tomotherapy to
overcome limitations of classical WBRT and allows se-
lective tailor-made dose escalation [28]. Furthermore,
Marsh et al. reported on the feasibility of neural stem
cell and hippocampus region sparing during WBRT by
using helical Tomotherapy and a “how-to” on helical
Tomotherapy for hippocampal-sparing WBRT was pub-
lished by Gondi et al. [29,30].
In the present randomized and prospective two-armed
trial, the toxicity of the radiotherapeutic treatment in pa-
tients with BM from MM treated with either WBRT or
whole brain helical Tomotherapy (WBHT) with integrated
boost and hippocampal-sparing will be investigated.Methods and design
Study design
The BRAIN-RT study is a prospective, randomized two-
arm exploratory study designed to generate information
on the safety and treatment response of WBHT with in-
tegrated boost and hippocampal-sparing for BM from
MM. The flow chart is found in Figure 1. After thor-
ough information patients have to provide a written in-
formed consent before being enrolled into this study.
Following the baseline assessments, the patients are
randomized to either experimental WBHT or conven-
tional WBRT:
Experimental arm 1: WBHT applying 30 Gy in 10
fractions to the whole brain with an integrated boost
of 50 Gy in 10 fractions to the BM. Furthermore,
hippocampal-sparing as low as reasonable achievable
should be aspired.
Conventional arm 2: WBRT applying 30 Gy in 10 frac-
tions to the whole brain.
Endpoints
The primary endpoint of this study is toxicity. The second-
ary endpoints are imaging response, local and loco-regional
Table 1 In- and exclusion criteria of the study
Inclusion criteria
Patients meeting all of the following criteria will be considered for
admission to the trial:
• histologically confirmed malignant melanoma (MM)
• MR-imaging confirmed >1 cerebral metastases
(in case of resection, >1 remaining metastases)
• age≥ 18 years of age
• Karnofsky Performance Score ≥60
• For women with childbearing potential, (and men) adequate
contraception.
• Ability of subject to understand character and individual
consequences of the clinical trial
• Written informed consent (must be available before enrolment in
the trial)
Exclusion criteria
Patients presenting with any of the following criteria will not be
included in the trial:
• refusal of the patients to take part in the study
• previous radiotherapy of the brain
• Patients who have not yet recovered from acute high-grade
toxicities of prior therapies
• Known carcinoma < 5 years ago (excluding Carcinoma in situ of the
cervix, basal cell carcinoma, squamous cell carcinoma of the skin)
requiring immediate treatment interfering with study therapy
• Pregnant or lactating women
• Participation in another clinical study or observation period of
competing trials, respectively
• MRI contraindication (i.e. cardiac pacemaker, implanted defibrillator,
certain cardiac valve replacements, certain metal implants)
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(QoL). The toxicity will be quantified according to the
common toxicity criteria (CTC) Version 4. The imaging re-
sponse will be evaluated according to the response evalu-
ation criteria in solid tumors (RECIST 1.1). QoL will be
measured using the European Organisation for Research
and Treatment of Cancer (EORTC)-QoL-Q C30 and brain
module BN-20. Furthermore, translational investigations
for immune monitoring will be performed. The endpoints
will be accessed after enclosure of the participants, at the
end of radiation therapy and every two months thereafter
up to a total of 12 months.
Patient selection criteria
The BRAIN-RT study encloses patients with magnetic res-
onance imaging (MRI) confirmed brain metastases (n > 1)
from a histopathologically confirmed malignant melan-
oma. All patients fulfilling the inclusion and exclusion cri-
teria will be informed about the possibility to participate
in the study. Registration for the study must be performed
prior to beginning of RT. The detailed in- and exclusion
criteria are listed in Table 1.
Ethical aspects
Approval by the ethics committee of the University of
Heidelberg (S-327/2012) and the Federal Office of Radi-
ation Protection (BfS) (Z 5-22461/2-2013-001) has been
obtained. The trial is registered at www.drks.de (trial ID:
DRKS00005127).
Radiation therapy/treatment planning and dose
prescription
Experimental arm 1: Patients will be immobilized using
an individually manufactured head mask. For treatment
planning, CT with and without contrast-enhancement as
well as MR-imaging will be performed for optimal target
definition. Organs at risk such as the brain stem, optic
nerves, chiasm, hippocampus and spinal cord will be
contoured. Dose constraints of normal tissue will be
respected according to the quantitative analyses of nor-
mal tissue effects in the clinic (QUANTEC) reports [31].
The clinical target volume (CTV) includes the whole
brain. PTV whole brain = CTV + 5 mm. The Gross
Tumor Volume (GTV) for the integrated boost will be
defined as the contrast-enhancing lesions on T1-
weighted MR-imaging. The Planning Target Volume
(PTV) will include a safety margin of up to 1–2 mm.
For low infratentorial lesions, the CTV may include the
whole brain down to the second cervical vertebra.
WBHT will be applied in 10 fractions with median sin-
gle doses of 3 Gy to the whole brain. The integrated
boost will be applied by median single doses of 5 Gy.
WBHT 10 × 3 Gy: The QUANTEC recommendations
are adhered. Hippocampus: ALARA.Integrated boost 10 × 5 Gy: Brain stem: < 73% (=bio-
logical 53,8 Gy @ α/β 2,1 Gy and reference dose 1,8 Gy),
Optic nerve/chiasm: <76% (=biological 53,8 Gy @ α/β
3,0 Gy and reference dose 1,8 Gy), Hippocampus:
ALARA, Spinal cord: <66% (=biological 46,0 Gy @ α/β
2,0 Gy and reference dose 1,8 Gy).
The target volume definition for WBHT is performed
using the following software: Nucletron Masterplan, Sie-
mens Dosimetrist and Oncologist. Treatment planning
is performed using the Tomotherapy planning software.
Prior to WBHT, patient positioning will be evaluated
using a megavoltage-CT. Treatment will be delivered
using 6 MeV photon beams.
Conventional arm 2: Patients will be immobilized
using an individually manufactured head mask. For
treatment planning, CT without contrast for a virtual
simulation will be performed. The CTV includes the
whole brain. WBRT will be delivered by opposed lateral
6 MeV photon beams. For low infratentorial lesions, the
CTV may include the whole brain down to the second
cervical vertebra. WBRT will be applied in 10 fractions
with single doses of 3 Gy to the whole brain.
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Study hypothesis and sample size
This exploratory study is designed to generate prelimin-
ary information on the safety and treatment response of
whole brain helical Tomotherapy with integrated boost
and hippocampal-sparing for BM from MM. The
intention-to-treat population consists of all patients who
signed an informed consent and met the inclusion cri-
teria. Each study-arm will include 25 patients. The
planned sample size relies on logistic considerations
based on the expected annual recruitment of patients af-
fected by MM with multiple BM.
Investigated samples/population
The primary analyses will be based on the complete set
of patients classified according to the intention-to-treat
principle (International Conference on Harmonisation,
1999). This data set includes all patients who were
treated at least once. The per-protocol set includes all
patients from the complete set without major protocol
deviations. The analysis of toxicity and safety will be
conducted based on all randomized patients who were
treated at least once.
Statistical methods
The primary endpoint is toxicity. Secondary endpoints are
imaging response, local and loco-regional progression-free
survival, overall survival and quality of life. Toxicity will be
quantified by absolute frequencies and percentages of side
effects according to CTC adverse event criteria version 4.
Imaging response will be evaluated according to the
RECIST criteria and represented by percentages. Kaplan-
Meier curves will be plotted and Cox-regression analyses
will be conducted to investigate possible factors influen-
cing survival. QoL will be measured with the EORTC-
QoL-Q C30 (http://groups.eortc.be/qol/eortc-qlq-c30)
and its brain module BN-20, the results will be summa-
rized by median, minimum and maximum scores, and
represented by box plots.
Discussion
The standardized incidence rates of malignant melan-
oma tripled in the last decades [1], therefore the man-
agement of malignant melanoma becomes more and
more important for the daily clinical routine. When
looking back to the stage dependant incidence rate,
about 10% of patients initially presenting with AJCC
Stage III disease are at risk for [4-7] and up to 46% of
stage IV patients will develop BM [8]. Due to the rela-
tively short survival time after initial diagnosis of mul-
tiple BM as well as low complete remission rates to
WBRT [19], management of BM remains a major chal-
lenge in the management of this disease. In patients with
only few and easily accessible BM surgical resection isstandard treatment, a resection of multiple BM is nor-
mally not indicated. Furthermore, systemic therapies do
not have proven equivalent effectiveness up to date [32].
With the development and clinical implementation of
new radiation therapy techniques as Tomotherapy or
other intensity-modulated arc techniques, especially if
using smaller collimation systems, the application of an
integrated boost to BM seems feasible [28] and might
promise an increased tumor response resulting in higher
remission rates while reducing treatment-related side ef-
fects by hippocampal-sparing at the same time [30]. A
recent Australian report on 30 patients treated with
volumetric modulated arc therapy for BM from mainly
MM concluded that treatment was feasible and yielded
comparable survival times and side effects compared to
standard radiosurgery with or without WBRT [33].
Even though helical Tomotherapy promises excellent
homogeneity and conformality in the setting of an inte-
grated boost for BM [28], this technique still has its limita-
tions when compared to a classical radiosurgery: in a plan
comparison on radiosurgery versus helical Tomotherapy
for arterio-venous malformations, all helical Tomotherapy
plans had a higher high-dose brain exposure while only
the regular helical Tomotherapy delivery using 0.6 cm
field width showed a better low-dose exposure [34]. On
the other hand since application is planned as an inte-
grated boost to whole brain radiotherapy, the high-dose
exposure should play a minor role. Furthermore, with the
implementation of dynamic jaws and dynamic couch the
total treatment time compared to regular delivery times as
well as dose penumbra and consecutively the integral dose
will be reduced [35].
Further aspects are the side effects caused by the inte-
gral dose to the whole brain. Unfortunately, there is only
limited data on the tolerance dose of the whole brain,
most publications available report on tolerance doses for
partial brain irradiations. According to the QUANTEC
reports, the risk for radiation induced necrosis of the
brain is below 3% in case of less than 60 Gy/2 Gy and
between 5% in case of a biologically equivalent dose
(BED) of 120 Gy (72 Gy/2 Gy) and 10% in case of a BED
of 150 Gy (90Gy / 2 Gy) and might increase with
hypofractionation. According to our BED calculation
one should aspire an integral dose to the whole brain
below 65% of the integrated boost dose, corresponding
to 44.9 Gy in 1.8 Gy fractions using an α/β of 2.0 Gy
and thereby staying below 2.5% risk for radiation necro-
sis as described in the RTOG low-grade glioma trial by
Shaw et al. [36].
Therefore, this randomized, prospective two-armed
phase I-II trial is primarily aimed at the safety by evalu-
ation of treatment related toxicity. Secondary p are the
imaging response, local and loco-regional tumor control,
overall survival and quality of life in patients treated
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from malignant melanoma. We assume that the treat-
ment results might be improved by additional dose es-
calation. In case of promising results, the information
generated in the present trial will be used to plan a con-
firmatory study.
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